Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Arizona
Clinical trial register · United States · industry-sponsored

Clinical Trials in Arizona, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9156 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 23 Oct 2026, 03:16 UTC
9156
Studies in scope
industry-sponsored, all four open statuses
4971
Recruiting now
open to new participants
2200
Lead sponsors
across recruiting studies
Top states
California 115 Florida 109 Massachusetts 65 Georgia 63 Illinois 62
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca113 Eli Lilly and Company97 AbbVie75 Merck Sharp & Dohme LLC62 Novartis Pharmaceuticals49 Clear sponsor filter
State
California115 Florida109 Massachusetts65 Georgia63 Illinois62
All 47 states
Target enrolment
to

Trials with a site in Arizona

49 of 9156 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Colorado, Georgia, Illinois, Maryland
2026-08-27
Recruiting
Novartis Pharmaceuticals
Phase 2
164
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Louisiana, Minnesota
2026-08-04
Recruiting
Novartis Pharmaceuticals
Phase 3
570
Arizona, Florida, Illinois, Massachusetts, Michigan, New Jersey, New York, North Carolina
2026-07-16
Recruiting
A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
NCT07498426Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Novartis Pharmaceuticals
Phase 3
300
Arizona, California, Colorado, Florida, Kentucky, Louisiana, Minnesota, Texas
2026-06-03
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Active, closed
Novartis Pharmaceuticals
Phase 2
7
Arizona, California, Florida, Nebraska
2025-09-11
Active, closed
Novartis Pharmaceuticals
Phase 2
97
Arizona, California, Florida, Hawaii, Kansas, Massachusetts, Missouri, Nevada
2025-08-07
Active, closed
Novartis Pharmaceuticals
Phase 3
409
Alabama, Arizona, Arkansas, California, Colorado, District of Columbia, Florida, Georgia
2025-07-11
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Iowa
2025-07-01
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Arizona, California, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-06-23
Recruiting
Novartis Pharmaceuticals
Phase 1/2
30
Arizona, California, Georgia, Pennsylvania, Texas
2025-06-02
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
DrugOctreotide LAR
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Active, closed
Novartis Pharmaceuticals
Phase 3
180
Arizona, California, District of Columbia, Florida, Illinois, Maryland, Massachusetts, Michigan
2025-02-07
Active, closed
Novartis Pharmaceuticals
Phase 3
588
Arizona, Arkansas, California, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-01-31
Recruiting
Novartis Pharmaceuticals
Phase 1/2
232
Arizona, California, Colorado, Florida, Georgia, Kansas, Kentucky, Massachusetts
2024-10-24
Active, closed
Novartis Pharmaceuticals
Phase 2
201
Arizona, California, Florida, Illinois, Michigan, New York, Tennessee, Texas
2024-10-09
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Arizona, Minnesota
2024-08-05
Active, closed
Novartis Pharmaceuticals
Phase 3
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Michigan, North Carolina
2024-07-31
Active, closed
Novartis Pharmaceuticals
Phase 3
162
Arizona, California, Florida, Maryland, Michigan, New Hampshire, Ohio, Texas
2024-06-28
Recruiting
Novartis Pharmaceuticals
Phase 3
1,444
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Recruiting
Novartis Pharmaceuticals
Phase 4
700
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Indiana
2023-08-14
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
226
Arizona, California, Colorado, Florida, Illinois, Indiana, Maryland, Massachusetts
2023-02-03
Active, closed
Novartis Pharmaceuticals
Phase 3
152
Arizona, Colorado, Illinois, Massachusetts, Michigan, Montana, New York
2023-02-02
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Active, closed
Novartis Pharmaceuticals
Phase 4
134
Arizona, Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana
2022-07-07
Active, closed
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
1,000
Arizona, Arkansas, California, Colorado, Delaware, District of Columbia, Florida, Illinois
2021-12-16
Active, closed
Novartis Pharmaceuticals
Phase 3
1,007
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana, Kansas
2021-12-13
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
2021-11-23
Recruiting
Novartis Pharmaceuticals
Phase 3
540
Arizona, California, Colorado, Delaware, Idaho, Illinois, Maryland, Massachusetts
2021-09-20
Active, closed
Novartis Pharmaceuticals
Phase 3
1,140
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2021-06-09
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2021-04-09
Active, closed
Pediatric Long-Term Follow-up and Rollover Study
NCT03975829Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma, Oligodendroglioma, Childhood
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
163
Arizona, District of Columbia, Florida, Indiana, Maryland, Massachusetts, Minnesota, New York
2019-11-04
Active, closed
Novartis Pharmaceuticals
Phase 2
121
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2019-06-24
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2018-12-07
Recruiting
Novartis Pharmaceuticals
Observational
700
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Indiana, Iowa
2018-09-25
Recruiting
Dabrafenib and/or Trametinib Rollover Study
NCT03340506Melanoma, Non Small Cell Lung Cancer, Solid Tumor, Rare Cancers
DrugsDabrafenib·Trametinib
Novartis Pharmaceuticals
Phase 4
100
Arizona, Maryland, Ohio, Texas
2018-01-26
Active, closed
Novartis Pharmaceuticals
Phase 3
206
Arizona, California, Colorado, Connecticut, Illinois, Minnesota, New Jersey, Ohio
2017-08-23
Recruiting
CAR-T Long Term Follow Up (LTFU) Study
NCT02445222Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
Novartis Pharmaceuticals
Phase 3
1,105
Arizona, California, Georgia, Illinois, Kansas, Massachusetts, Michigan, Minnesota
2015-11-02
Active, closed
Novartis Pharmaceuticals
Phase 1
57
Arizona, Massachusetts, Pennsylvania
2015-05-27
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 October 2026. https://priyalifescience.com/clinical-trials-usa/state/arizona

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,156 studies in total at the last sync on 23 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Arizona that also match the filters currently applied.

How many clinical trials are recruiting in Arizona?

17 of the 49 studies on this page are recruiting new participants as of the 23 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 32 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Arizona), 49 studies
PhaseStudiesRecruitingShare
Phase 3311063.3%
Phase 28116.3%
Phase 45210.2%
Phase 1/2224.1%
Observational112%
Phase 1102%
Phase 2/3112%

Most active sponsors

Lead sponsors with the most studies (Arizona)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals4917
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.